4.6 Article

Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial

Journal

BMJ OPEN
Volume 11, Issue 3, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2020-043929

Keywords

haematology; immunology; oncology; qualitative research; clinical trials

Funding

  1. Clinical Social and Economic Impact (CSEI) grant from Biotherapeutics for Cancer Treatment (BioCanRx) [FY17/CSEI4]
  2. Government of Canada's Networks of Centres of Excellence
  3. Ottawa Hospital Anesthesia Alternate Funds Association
  4. Department of Anesthesiology and Pain Medicine, Ottawa

Ask authors/readers for more resources

Using the Theoretical Domains Framework (TDF), this study identified various factors that influence patient participation in early phase CAR-T cell therapy trials, including patient interests in treatment safety, efficacy, trial logistics, altruism, personal health benefits, medical advice from healthcare providers, and access to financial and social supports. These findings can help optimize recruitment processes and enhance patient engagement in clinical trials.
Objectives Bench to bedside translation of groundbreaking treatments like chimeric antigen receptor T (CAR-T) cell therapy depends on patient participation in early phase trials. Unfortunately, many novel therapies fail to be adequately evaluated due to low recruitment rates, which slows patient access to emerging treatments. Using the Theoretical Domains Framework (TDF), we sought to identify potential patient barriers and enablers to participating in an early phase CAR-T cell therapy trial. Design We used qualitative semistructured interviews to identify potential barriers and enablers to patients' hypothetical participation in an early phase CAR-T cell therapy trial. We used the TDF and directed content analysis to identify relevant domains based on frequency, relevance and the presence of conflicting beliefs. Participants Canadian adult patients diagnosed with haematological malignancies. Results In total, we interviewed 13 participants (8 women, 5 men). Participants ranged in age from 18 to 73 (median=56) and had been living with haematological cancer from a few months to several years. We found participants were unfamiliar with CAR-T cell therapy but wished to know more about treatment safety, efficacy and trial logistics (domains: knowledge, beliefs about consequences). They were motivated by altruistic considerations, though many prioritised personal health benefits despite recognising the goals (ie, establishing safety) of early phase clinical trials (domains: goals, intentions). Every participant valued receiving medical advice from their haematologists and oncologists, though some preferred impartial medical experts to inform their decision making (domain: social influences). Finally, participants indicated that improving access to financial and social supports would improve their trial participation experience (domain: environmental context and resources). Conclusion Using the TDF allowed us to identify factors that might undermine participation to a CAR-T cell therapy trial and to optimise recruitment processes by considering patient perspectives to taking part in early phase trials. Trial regestration: NCT03765177; Pre-results.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available